KPNA2 promotes migration and invasion in epithelial ovarian cancer cells by inducing epithelial-mesenchymal transition via Akt/GSK-3β/Snail activation.

Background: Increased karyopherin alpha 2 (KPNA2) expression has been demonstrated in epithelial ovarian carcinoma (EOC) tissue. However, its role in the disease is not clear. Here, we investigate the mechanism of involvement of KPNA2 in EOC.
Methods: Stable cell lines expressing KPNA2, or KPNA2 shRNAs, were constructed. The effects of KPNA2 overexpression and knockdown on EOC cell migration, invasion, and epithelial-to-mesenchymal transition (EMT) were evaluated using relevant assays and western blot analysis. Key components of the Akt/GSK-3β/Snail signaling pathway were detected using western blotting and immunofluorescence.
Results: KPNA2 overexpression increased the migration and invasion of EOC cells (EFO-21 and SK-OV3); these cells also exhibited characteristics of EMT. Key proteins in the Akt/GSK-3β/Snail signaling pathway were also upregulated in cells overexpressing KPNA2. In contrast, knockdown of KPNA2 effectively suppressed migration and invasion of these EOC cells. Conclusions: KPNA2 may reduce the migration and invasion of EOC by inhibiting the Akt/GSK-3β/Snail signaling pathway and suppressing EMT.

Introduction

Epithelial ovarian carcinoma (EOC) kills more women than any other gynecological malignancy. In 2014, it is estimated there were >14,000 EOC deaths and nearly 22,000 new cases 1. The condition is often diagnosed late (at an advanced stage) and has a high metastasis rate. It is therefore crucial to understand the molecular mechanisms of EOC and to improve the available therapies.

Deregulation of cellular transport machinery occurs frequently in tumors. Increased expression of karyopherin alpha 2 (KPNA2), a protein that functions in nucleocytoplasmic transport, has been shown in melanoma 2, and cancers of the cervix 3, esophagus 4, lung 5, prostate 6, brain 7, liver 8, and bladder 9. KPNA2 is overexpressed in human EOC tissues and cell lines 10, and overexpression is correlated with poor prognosis in EOC 10. Nevertheless, the mechanism of KPNA2 in EOC pathogenesis remains to be conclusively determined. Here, we investigated the effects of KPNA2 overexpression and knockdown in EOC cell lines in vitro.

Materials and Methods

Cell culture

Ovarian cancer cell lines SKOV3 and EFO21 were grown in Dulbecco's Modified Eagle's Medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; HyClone, Logan, UT, USA) and 1% penicillin-streptomycin. Cells were cultured at 37°C under a humidified atmosphere containing 5% CO2.

To overexpress KPNA2, a full-length human KPNA2 cDNA was ligated into plasmid pMSCV. To knockdown KPNA2, short hairpin (sh) RNA sequences were cloned into pSuper-retro-puro (Langri, GuangZhou, China) to generate RNAis with sequences RNAi#1, 5′-ATTTACAGTGCCCTGGTTG-3′ and RNAi#2, 5′-TTAACGAAGCC TTATACAC-3′. Transfection of plasmids used Lipofectamine 2000 reagent (Invitrogen) according to the manufacturer's protocol. Cell lines stably-expressing KPNA2 or the KPNA2 shRNAs were treated with 0.5 mg/mL puromycin for 10 days.

Western blot assays

Western blot analysis was performed according to standard methods, as previously described 10, using anti-KPNA2 (Abcam, Cambridge, UK), anti-total Akt, anti-p-Akt, anti-total GSK-3β, anti-p-GSK-3β, anti-snail, anti-twist, anti-vimentin, anti-E-cadherin, anti-Fibronectin, and anti-α-catenin antibodies (Cell Signaling Technology, Danvers, MA, USA). Polyvinylidene fluoride membranes were stripped and re-blotted with an anti-β-actin monoclonal antibody (Sigma, St. Louis, MO, USA) as a loading control.

Wound-healing assay

Cells (2×106) were seeded into 35-mm Petri dishes. After 12-h of incubation, a wound was created using a P200 pipette tip. Microscopic images were recorded immediately (0 h) and after 8 and 16 h.

Invasion assays

Cell invasiveness used Matrigel-coated Invasion Chambers (8 μm; BD Biosciences, San Jose, CA) according to the manufacturer's protocol. Transfected cells (~25,000 per well) were resuspended in serum-free medium, then transferred to the upper chamber of a Matrigel-coated insert. Medium in the lower chamber included 10% FBS. Cells were incubated at 37°C for 24 h, then cells on the upper surface were removed and discarded. Cells that had invaded the lower surface were fixed and stained with 0.05% crystal violet for 30 min and counted microscopically.

Immunofluorescence analysis

Cells were incubated briefly with primary antibodies against α-catenin, vimentin, E-cadherin or N-cadherin, and then incubated with rhodamine-conjugated or FITC-conjugated goat anti-rabbit or anti-mouse IgG. Coverslips were counterstained with 4',6-diamidino-2-phenylindole. Images were collected using a confocal laser-scanning microscope (FV1000, Olympus) and processed in Adobe Photoshop 7.0.

Statistical analysis

Statistical analysis was performed using the SPSS software package (version 16.0, SPSS). A P-value of <0.05 was considered statistically significant. For the in vitro studies, statistical significance was verified using a Student's t-test (two tailed).

Results

KPNA2 is essential for EOC cell migration and invasion

EFO-21 and SK-OV3 cell lines were used to stably-express KPNA2 cDNA (i.e., EFO-21/KPNA2 and SK-OV3/KPNA2) and KPNA2 shRNAs (i.e., EFO-21/siKPNA2#1, EFO-21/siKPNA2#2, SK-OV3/siKPNA2#1, and SK-OV3/siKPNA2#2). In wound-healing assays, upregulation of KPNA2 expression significantly increased migration and invasion of EOC cells, while downregulation of KPNA2 expression significantly reduced migration and invasion of EOC cells (P < 0.05; Fig. Moreover, the invasiveness of EOC cells were dramatically expedited by the upregulation of KPNA2 expression, and impeded by the downregulation of KPNA2 expression, as shown in the invasion assays (Fig.

KPNA2 promotes epithelial-to-mesenchymal transition (EMT) and activates the Akt/GSK-3β/Snail pathway

Overexpression of KPNA2 augmented the expression of mesenchymal markers such as vimentin, fibronectin, and N-cadherin but inhibited the expression of epithelial markers (including α-catenin), as well as E-cadherin (Fig. ). Alternatively, knockdown of KPNA2 suppressed the expression of mesenchymal markers but enhanced the expression of epithelial markers (Figs. ). Upregulating KPNA2 also increased the expression of phosphorylated Akt, but not total Akt; the expression of Snail, Twist, and phosphorylated GSK-3β were also upregulated, but not total GSK-3β (Fig. ). Meanwhile, silencing KPNA2 repressed the expression of Snail, Twist, and phosphorylated Akt/GSK-3β (Figs. ).

Discussion

KPNA2 mediates signaling factor import into the nucleus, and export of response molecules to the cytoplasm 12. KPNA2 is suggested to be involved in a variety of malignancies, but the mechanism remains uncertain 2, 13. Previously, we showed that that mir-26b suppresses EOC cell growth and metastasis by decreasing KPNA2 and octamer-binding transcription factor 4 expression 14. The key outcome of the present work is that migration and invasion of EOC cells were significantly increased by KPNA2 overexpression. Such overexpression also resulted in an increase in the EMT characteristics of EOC cells: epithelial cell markers were decreased and mesenchymal markers were increased. EMT is important for invasion, metastasis and drug-resistance of cancer cells 15.

EMT is regulated by various signaling pathways, including nuclear factor kappa B, Wnt, transforming growth factor-β, Notch, and Akt/GSK-3β/Snail 15. Overexpression of KPNA2 increased the expression of phosphorylated Akt and GSK-3β, whereas knockdown of KPNA2 decreased them. The latter effect was probably mediated by inhibition of c-Myc transactivity and Akt kinase activity, and suppression of FOXO3a activity 16. FOXO3a is a transcription factor whose activity is principally regulated by post-translational modification (PTM) and nuclear-cytoplasmic shuttling; PI3K/AKT pathway-regulated phosphorylation is the principal PTM that controls the subcellular localization of FOXO3a 17, 18. In addition, Spalt Like Transcription Factor 4, which is an EMT and drug-resistance inducer, was shown to induce EMT by regulating c-Myc 19, and activated FOXO3a played a key role in doxorubicin-induced EMT in hepatocellular carcinoma cells 20. The findings of the present study strongly suggest that KPNA2 functions as an oncogenic protein in the development and progression of EOC. Downregulation of KPNA2 significantly decreases the invasiveness of EOC cells and reverses EMT by inhibiting the Akt/GSK-3β/Snail pathway.

We propose a mechanism for the role of KPNA2 in EOC pathogenesis: KPNA2 may transport c-Myc into the nucleus where it regulates transactivity, triggering Akt/GSK-3β/Snail pathway-mediated EMT and subsequent metastasis (Fig. ). Further research is underway to validate both this hypothesis and KPNA2 as a therapeutic target for EOC.